GDRX vs OMCL
GDRX: GoodRx is a leading digital healthcare platform that provides price transparency and discount tools to help Americans save money on prescription medications and access healthcare services. OMCL: Omnicell empowers hospitals and health systems with automated medication management and intelligence solutions to drive clinical, operational, and financial efficiency.
Side-by-side fundamentals
| Metric | GDRX | OMCL | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $3.80 | $36.86 | |
| Market cap as of 2026-08-12 | $1.2B | $1.7B | |
| P/E as of 2026-08-12 | 76.84 | 43.33 | OMCL lower |
| PEG as of 2026-08-12 | -47.17 | 2.97 | GDRX lower |
| Net margin as of 2026-08-12 | +2.1% | +3.1% | OMCL higher |
| Gross margin as of 2026-08-12 | +90.8% | +44.8% | GDRX higher |
| Operating margin as of 2026-08-12 | +9.5% | +4.7% | GDRX higher |
| ROE as of 2026-08-12 | +2.6% | +3.1% | OMCL higher |
| ROA as of 2026-08-12 | +0.9% | +2.0% | OMCL higher |
| Debt / equity as of 2026-08-12 | 0.75 | 0.13 | OMCL lower |
| Revenue growth (YoY) as of 2026-08-12 | -1.8% | +8.4% | OMCL higher |
| Revenue CAGR (3y) SEC XBRL | +1.3% | -2.9% | GDRX higher |
| Beta as of 2026-08-12 | 1.72 | 1.00 | |
| 1-year return as of 2026-08-11 close | +9.2% | +19.6% | OMCL higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.